The other AI biotech company that Recursion is merging with before early 2025, Exscientia, counts Merck, Sanofi, and Bristol Myers Squibb among its collaborators. Many of the other major players ...

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More ...

The most recent trading session ended with Recursion Pharmaceuticals (RXRX) standing at $6.11, ... Stock Dips While Market Gains: Key Facts October 02, 2024 — 05:50 pm EDT.

REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitors REC ...

3 Key Trends That Are Bullish for Recursion Pharmaceuticals Stock. Alex Carchidi, The Motley Fool . Sat, Oct 26, 2024, 9:00 AM 5 min read. In This Article: ... Enter Recursion, ...

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More Jan. 07, 2025 9:15 ...